India’s pharmaceutical industry is evolving into a global powerhouse, driven by innovation, vaccine leadership, and enhanced clinical capabilities, as noted by Dr. Elias Zerhouni, former Director of the US National Institutes of Health (NIH). The healthcare and biotechnology relationship between India and the US has progressed significantly, moving beyond mere manufacturing to innovation-focused collaboration. Notably, larger Indian companies like Lupin and Sun Pharma are increasingly involved in this partnership.
Dr. Zerhouni emphasized India’s strong presence in generics and active pharmaceutical ingredients (APIs), which are crucial components of the global drug supply chain. While India excels in generics, its role has expanded to include vaccine manufacturing, with institutions like the India Serum Institute playing a vital role in global immunization efforts. India’s approach to “frugal innovation,” characterized by cost-effective solutions, has been lauded as a distinguishing factor in the industry.
The COVID-19 pandemic exposed vulnerabilities in global supply chains, prompting a reassessment of health security measures worldwide. Dr. Zerhouni highlighted the need for private-sector collaboration, particularly between India and the US, to address such challenges effectively. Bureaucratic delays in grant approvals have been identified as a hurdle in fostering collaborations, necessitating streamlined processes for smoother operations.
Reflecting on the healthcare landscapes of the US and India, Dr. Zerhouni noted contrasting challenges. While the US grapples with high healthcare costs, hindering access to expensive medications, India focuses on expanding healthcare accessibility. The advent of artificial intelligence in the sector has enhanced operational efficiency, although its transformative impact remains gradual. Dr. Zerhouni emphasized the multipolar nature of biotechnology innovation, with countries like India and China contributing significantly to advancements in the field.
